Apriem Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Apriem Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500	Closed	-$24K	–	569
2015 Q2	$24K	Buy	+500	New	+$21.2K	0.01%	297

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Apriem Advisors's NBIX Position: Q3 2015 in Review

Apriem Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 500 shares — an estimated $24K sold.

Apriem Advisors first reported a position in NBIX in Q2 2015 and held it in 1 quarter. The position peaked at $24K in Q2 2015. 207 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

Apriem Advisors reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
Apriem Advisors sold 500 Neurocrine Biosciences shares in Q3 2015, an estimated $24K.
Apriem Advisors first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 1 quarter.
Apriem Advisors's Neurocrine Biosciences position peaked at $24K in Q2 2015.
207 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.